Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis

BACKGROUND AND PURPOSE: In 2011, fingolimod was approved in Switzerland for the treatment of relapsing‐remitting multiple sclerosis (RRMS). The aim of the present study was to assess the effectiveness and retention of fingolimod in a real‐life Swiss setting, in which patients can receive fingolimod...

Descripción completa

Detalles Bibliográficos
Autores principales: Zecca, C., Roth, S., Findling, O., Perriard, G., Bachmann, V., Pless, M. L., Baumann, A., Kamm, C. P., Lalive, P. H., Czaplinski, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969089/
https://www.ncbi.nlm.nih.gov/pubmed/29431876
http://dx.doi.org/10.1111/ene.13594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969089/
https://www.ncbi.nlm.nih.gov/pubmed/29431876
http://dx.doi.org/10.1111/ene.13594

Ejemplares similares